We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

INO's latest try at bringing a treatment to market is INO-3107, for which it expects to submit a BLA in the second half of 2024. Potential market size if the BLA is successful is $770 million ...

Neuroophthalmologic abnormalities associated with multiple sclerosis, including acute demyelinating optic neuritis and internuclear ophthalmoplegia, are described in detail. Current and emerging ...

As of May 3 at 11:17 AM EDT. Market Open.

As of April 26 at 9:38 AM EDT. Market Open.

DON is the most common entity to affect the afferent visual pathways in MS, while saccadic abnormalities, INO, smooth pursuit abnormalities and abnormalities of the VOR are among the more common ...

Q: My friends have noticed that my eyelids have become droopy over the last six months, and now I occasionally see double. I am only 29. I think my cousin had similar symptoms when she was my age ...

INO-6172 is under clinical development by Inovio Pharmaceuticals and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human ...